Neurocrine Biosciences (NASDAQ:NBIX) Issues Quarterly Earnings Results

Neurocrine Biosciences (NASDAQ:NBIX) announced its earnings results on Thursday. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62), Zacks reports. Neurocrine Biosciences had a return on equity of 15.68% and a net margin of 17.21%.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX opened at $150.51 on Friday. Neurocrine Biosciences has a 1-year low of $110.95 and a 1-year high of $157.98. The business’s 50 day moving average is $138.41 and its two-hundred day moving average is $131.64. The stock has a market capitalization of $15.24 billion, a P/E ratio of 40.35 and a beta of 0.33.

Analyst Ratings Changes

A number of research firms have commented on NBIX. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. UBS Group raised their price objective on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. BMO Capital Markets dropped their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. Morgan Stanley increased their price target on Neurocrine Biosciences from $170.00 to $185.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday. Five equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $167.43.

Insider Activity

In other news, insider Ingrid Delaet sold 1,091 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the sale, the insider now directly owns 2,507 shares in the company, valued at approximately $338,445. This represents a 30.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Kevin Charles Gorman sold 146,105 shares of the business’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $149.46, for a total value of $21,836,853.30. Following the transaction, the director now owns 514,596 shares of the company’s stock, valued at approximately $76,911,518.16. The trade was a 22.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 222,693 shares of company stock valued at $32,718,279 in the last ninety days. Insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.